Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
26
CSTL Quote, Financials, Valuation and Earnings
Last price:
$25.35
Seasonality move
:
-10.58%
Day range:
$25.82 - $26.64
52-week range:
$14.59 - $44.28
Dividend yield:
0%
P/E ratio:
30.24x
P/S ratio:
2.14x
P/B ratio:
1.60x
Volume:
388.1K
Avg. volume:
464.6K
1-year change:
33.73%
Market cap:
$752.8M
Revenue:
$344.2M
EPS (TTM):
-$0.85
Analysts' Opinion
-
Consensus RatingCastle Biosciences, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $48.50, Castle Biosciences, Inc. has an estimated upside of 91.55% from its current price of $26.13.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $44.00 representing 100% downside risk from its current price of $26.13.
Fair Value
-
According to the consensus of 8 analysts, Castle Biosciences, Inc. has 91.55% upside to fair value with a price target of $48.50 per share.
CSTL vs. S&P 500
-
Over the past 5 trading days, Castle Biosciences, Inc. has underperformed the S&P 500 by -9.76% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Castle Biosciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Castle Biosciences, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Castle Biosciences, Inc. reported revenues of $87M.
Earnings Growth
-
Castle Biosciences, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Castle Biosciences, Inc. reported earnings per share of -$0.08.
Enterprise value:
490.3M
EV / Invested capital:
0.97x
Price / LTM sales:
2.14x
EV / EBIT:
11.64x
EV / Revenue:
1.42x
PEG ratio (5yr expected):
-0.54x
EV / Free cash flow:
17.31x
Price / Operating cash flow:
26.05x
Enterprise value / EBITDA:
78.26x
Gross Profit (TTM):
$236.3M
Return On Assets:
-4.36%
Net Income Margin (TTM):
-7.02%
Return On Equity:
-5.28%
Return On Invested Capital:
-4.92%
Operating Margin:
-4.4%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $219.8M | $332.1M | $344.2M | $86.3M | $87M | |
| Gross Profit | $164.2M | $258.8M | $236.3M | $65.3M | $66M | |
| Operating Income | -$68M | $8.7M | -$42.8M | $4.1M | -$3.8M | |
| EBITDA | -$55.6M | $24.7M | -$2M | $9.8M | -$50K | |
| Diluted EPS | -$2.15 | $0.61 | -$0.85 | $0.32 | -$0.08 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $353.7M | $292.3M | $295.6M | $360.2M | $361.1M | |
| Total Assets | $462.6M | $474M | $477.8M | $553.9M | $609.2M | |
| Current Liabilities | $24.9M | $36.1M | $47.7M | $49.4M | $68.7M | |
| Total Liabilities | $50.8M | $74.9M | $86.5M | $98.1M | $138.3M | |
| Total Equity | $411.7M | $399.2M | $391.3M | $455.8M | $470.9M | |
| Total Debt | $6.9M | $11.5M | $14.2M | $24.8M | $35.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$135K | $71.6M | $64.3M | $31.1M | $26.9M | |
| Cash From Investing | -$16.2M | -$50.1M | -$60.4M | $5.8M | $8.8M | |
| Cash From Financing | -$2.3M | $6.1M | -$7M | -$5.4M | -$4.6M | |
| Free Cash Flow | -$13.8M | $43.2M | $28.3M | $23.5M | $19.7M | |
CSTL
Sector
Market Cap
$752.8M
$25.8M
Price % of 52-Week High
57.18%
49.8%
Dividend Yield
0%
0%
Shareholder Yield
-0.37%
-1.68%
1-Year Price Total Return
28.99%
-17.36%
Beta (5-Year)
1.088
0.492
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$27.31
200-day SMA
Sell
Level
$27.19
Bollinger Bands (100)
Sell
Level
28.42 - 40.4
Chaikin Money Flow
Sell
Level
-1.5M
20-day SMA
Sell
Level
$29.74
Relative Strength Index (RSI14)
Sell
Level
27.16
ADX Line
Sell
Level
47.91
Williams %R
Buy
Level
-93.9944
50-day SMA
Sell
Level
$35.29
MACD (12, 26)
Buy
Level
1.52
25-day Aroon Oscillator
Sell
Level
-96
On Balance Volume
Sell
Level
-4.5M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.4022)
Buy
CA Score
(Annual)
Level (0.7976)
Buy
Beneish M-Score
(Annual)
Level (-3.3867)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-2.4278)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Castle Biosciences, Inc.is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett’s esophagus, uveal melanoma, and in the treatment of mental health conditions. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
Stock Forecast FAQ
In the current month, CSTL has received 8 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CSTL average analyst price target in the past 3 months is $48.50.
-
Where Will Castle Biosciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Castle Biosciences, Inc. share price will rise to $48.50 per share over the next 12 months.
-
What Do Analysts Say About Castle Biosciences, Inc.?
Analysts are divided on their view about Castle Biosciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Castle Biosciences, Inc. is a Sell and believe this share price will drop from its current level to $44.00.
-
What Is Castle Biosciences, Inc.'s Price Target?
The price target for Castle Biosciences, Inc. over the next 1-year time period is forecast to be $48.50 according to 8 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CSTL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Castle Biosciences, Inc. is a Buy. 8 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CSTL?
You can purchase shares of Castle Biosciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Castle Biosciences, Inc. shares.
-
What Is The Castle Biosciences, Inc. Share Price Today?
Castle Biosciences, Inc. was last trading at $25.35 per share. This represents the most recent stock quote for Castle Biosciences, Inc.. Yesterday, Castle Biosciences, Inc. closed at $26.13 per share.
-
How To Buy Castle Biosciences, Inc. Stock Online?
In order to purchase Castle Biosciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CSTL Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CSTL
Sector
P/E ratio
30.24x
21.71x
PEG ratio
-0.54x
-0.01x
P/B ratio
1.60x
1.78x
Price / LTM sales
2.14x
1.49x
Growth Metrics
CSTL
Sector
Revenue growth
0.81%
3.28%
Earnings growth
-125.03%
11.93%
Revenue (5-year growth)
40.6%
6.26%
Earnings forecast
-$0.26
-$0.20
Profitability
CSTL
Sector
Profitability FY 2025
$236.3M
$2.3M
Return on invested capital
-4.92%
-33.25%
Return on assets
-4.36%
-29.94%
Return on equity
-5.28%
-40.01%
Earnings Date
Last Earnings Date
Feb
26
Next Earnings Date
May
4
Estimated Next Earnings Date
May
28
Balance Sheet
CSTL
Sector
Total cash
$299.5M
$25M
Short term investments
$173.4M
$23.2M
Total assets
$609.2M
$70.1M
Long term debt
$35.7M
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 29x
Alerts
Buy
52
PZZA alert for Mar 12
Papa John's International, Inc. [PZZA] is down 7.08% over the past day.
Buy
53
NBIS alert for Mar 12
Nebius Group NV [NBIS] is down 3.56% over the past day.
Buy
88
NBTX alert for Mar 12
Nanobiotix SA [NBTX] is down 4.42% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
